Protocol Ledger

NCT03899337 · Phase II · ACTIVE NOT RECRUITING

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

Interventional Phase II clinical trial protocol NCT03899337 sponsored by University of Birmingham in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-23 Enrollment: 72 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03899337
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)72 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03899337
Protocol FieldVerified Registry Value
NCT IdentifierNCT03899337
Consolidated Lead SponsorUniversity of Birmingham
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment72 participants (ACTUAL)
Registered Start Date2019-07-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03899337
Hospital Research SiteLocationSite Profile
University Hospital of WalesCardiff, United KingdomOpen Hospital Dossier ->
Beatson West of Scotland Cancer CentreGlasgow, United KingdomOpen Hospital Dossier ->
Leicester Royal InfirmaryLeicester, United KingdomOpen Hospital Dossier ->
King's College HospitalLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI